EGFR and neoplasm: Conversely, blocking ERK signaling activity through expression of a dominant-negative form of EGFR (Buff et al., 1998) (Fig. 4I-N) and ERK and Ras RNAi constructs (Fig. S13) led to a reduction in scrib and dlg mutant tumor sizes at later stages.